Quality by Design: Development of Safe and Efficacious Full-Thickness Acellular Dermal Matrix Based on EuroGTPII Methodologies
The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal matrix, with high mechanical properties to be used in tendon repair surgeries and abdominal wall reconstruction, has determined the need for qualit...
Saved in:
Published in | Therapeutics and clinical risk management Vol. 19; pp. 567 - 578 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2023
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal matrix, with high mechanical properties to be used in tendon repair surgeries and abdominal wall reconstruction, has determined the need for quality by design process in order to assess evidence of quality, safety and efficacy. The EuroGTPII methodologies were specifically tailored to perform the risk assessment, identify and suggest tests in order to mitigate the potential risk consequences of a novel tissue preparation implementation.
The new allograft and associated preparation processes were assessed using the EuroGTP methodologies and characterized to properly evaluate the novelty (Step 1), identify and quantify the potential risks and risk consequences (Step 2), and define the extent of pre-clinical and clinical assessments required to mitigate the risks identified in the assessment (Step 3).
Four risk consequences associated with the preparation process were identified: (i) implant failure related with tissue procurement and the reagents used during the decellularization protocol; (ii) unwanted immunogenicity related with the processing; (iii) disease transmission linked with the processing, reagents used, reduction in the reliability of microbiology testing and the storage conditions; and (iv) toxicity related to the reagents used and handling of the tissue during clinical application. The outcome of the risk assessment was a low level of risk. Nevertheless, it determined the need for a series of risk mitigation strategies proposed to reduce each individual risk and to provide additional evidence of the safety and efficacy of full-thickness acellular dermal matrix grafts.
EuroGTPII methodologies allow us to identify the risks and ensure the correct definition of pre-clinical assessments required to address and mitigate the potential risk consequences, before proceeding with clinical use of the new allografts in patients. |
---|---|
AbstractList | Background: The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal matrix, with high mechanical properties to be used in tendon repair surgeries and abdominal wall reconstruction, has determined the need for quality by design process in order to assess evidence of quality, safety and efficacy. The EuroGTPII methodologies were specifically tailored to perform the risk assessment, identify and suggest tests in order to mitigate the potential risk consequences of a novel tissue preparation implementation. Methods: The new allograft and associated preparation processes were assessed using the EuroGTP methodologies and characterized to properly evaluate the novelty (Step 1), identify and quantify the potential risks and risk consequences (Step 2), and define the extent of pre-clinical and clinical assessments required to mitigate the risks identified in the assessment (Step 3). Results: Four risk consequences associated with the preparation process were identified: (i) implant failure related with tissue procurement and the reagents used during the decellularization protocol; (ii) unwanted immunogenicity related with the processing; (iii) disease transmission linked with the processing, reagents used, reduction in the reliability of microbiology testing and the storage conditions; and (iv) toxicity related to the reagents used and handling of the tissue during clinical application. The outcome of the risk assessment was a low level of risk. Nevertheless, it determined the need for a series of risk mitigation strategies proposed to reduce each individual risk and to provide additional evidence of the safety and efficacy of full-thickness acellular dermal matrix grafts. Conclusion: EuroGTPII methodologies allow us to identify the risks and ensure the correct definition of pre- clinical assessments required to address and mitigate the potential risk consequences, before proceeding with clinical use of the new allografts in patients. Keywords: EuroGTPII methodology, acellular dermis, risk assessment, quality, safety The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal matrix, with high mechanical properties to be used in tendon repair surgeries and abdominal wall reconstruction, has determined the need for quality by design process in order to assess evidence of quality, safety and efficacy. The EuroGTPII methodologies were specifically tailored to perform the risk assessment, identify and suggest tests in order to mitigate the potential risk consequences of a novel tissue preparation implementation. The new allograft and associated preparation processes were assessed using the EuroGTP methodologies and characterized to properly evaluate the novelty (Step 1), identify and quantify the potential risks and risk consequences (Step 2), and define the extent of pre-clinical and clinical assessments required to mitigate the risks identified in the assessment (Step 3). Four risk consequences associated with the preparation process were identified: (i) implant failure related with tissue procurement and the reagents used during the decellularization protocol; (ii) unwanted immunogenicity related with the processing; (iii) disease transmission linked with the processing, reagents used, reduction in the reliability of microbiology testing and the storage conditions; and (iv) toxicity related to the reagents used and handling of the tissue during clinical application. The outcome of the risk assessment was a low level of risk. Nevertheless, it determined the need for a series of risk mitigation strategies proposed to reduce each individual risk and to provide additional evidence of the safety and efficacy of full-thickness acellular dermal matrix grafts. EuroGTPII methodologies allow us to identify the risks and ensure the correct definition of pre-clinical assessments required to address and mitigate the potential risk consequences, before proceeding with clinical use of the new allografts in patients. BackgroundThe activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal matrix, with high mechanical properties to be used in tendon repair surgeries and abdominal wall reconstruction, has determined the need for quality by design process in order to assess evidence of quality, safety and efficacy. The EuroGTPII methodologies were specifically tailored to perform the risk assessment, identify and suggest tests in order to mitigate the potential risk consequences of a novel tissue preparation implementation. MethodsThe new allograft and associated preparation processes were assessed using the EuroGTP methodologies and characterized to properly evaluate the novelty (Step 1), identify and quantify the potential risks and risk consequences (Step 2), and define the extent of pre-clinical and clinical assessments required to mitigate the risks identified in the assessment (Step 3). ResultsFour risk consequences associated with the preparation process were identified: (i) implant failure related with tissue procurement and the reagents used during the decellularization protocol; (ii) unwanted immunogenicity related with the processing; (iii) disease transmission linked with the processing, reagents used, reduction in the reliability of microbiology testing and the storage conditions; and (iv) toxicity related to the reagents used and handling of the tissue during clinical application. The outcome of the risk assessment was a low level of risk. Nevertheless, it determined the need for a series of risk mitigation strategies proposed to reduce each individual risk and to provide additional evidence of the safety and efficacy of full-thickness acellular dermal matrix grafts. ConclusionEuroGTPII methodologies allow us to identify the risks and ensure the correct definition of pre-clinical assessments required to address and mitigate the potential risk consequences, before proceeding with clinical use of the new allografts in patients. Patricia López-Chicón,1,2,* Maria Luisa Pérez,1,3,* Cristina Castells-Sala,1,2,* Rita A Piteria,1,2,* Oscar Fariñas,1,2 Jaime Tabera,1,2 Anna Vilarrodona1,3 1Barcelona Tissue Bank (BTB), Banc de Sang i Teixits (BST), Barcelona, Spain; 2Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain; 3Vall Hebron Institute of Research (VHIR), Barcelona, Spain*These authors contributed equally to this workCorrespondence: Maria Luisa Pérez, Barcelona Tissue Bank (BTB), Banc de Sang i Teixits (BST, GenCAT), Passeig Taulat 116, Barcelona, E-08005, Spain, Tel +34 935 57 35 00, Email mlperez@bst.catBackground: The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal matrix, with high mechanical properties to be used in tendon repair surgeries and abdominal wall reconstruction, has determined the need for quality by design process in order to assess evidence of quality, safety and efficacy. The EuroGTPII methodologies were specifically tailored to perform the risk assessment, identify and suggest tests in order to mitigate the potential risk consequences of a novel tissue preparation implementation.Methods: The new allograft and associated preparation processes were assessed using the EuroGTP methodologies and characterized to properly evaluate the novelty (Step 1), identify and quantify the potential risks and risk consequences (Step 2), and define the extent of pre-clinical and clinical assessments required to mitigate the risks identified in the assessment (Step 3).Results: Four risk consequences associated with the preparation process were identified: (i) implant failure related with tissue procurement and the reagents used during the decellularization protocol; (ii) unwanted immunogenicity related with the processing; (iii) disease transmission linked with the processing, reagents used, reduction in the reliability of microbiology testing and the storage conditions; and (iv) toxicity related to the reagents used and handling of the tissue during clinical application. The outcome of the risk assessment was a low level of risk. Nevertheless, it determined the need for a series of risk mitigation strategies proposed to reduce each individual risk and to provide additional evidence of the safety and efficacy of full-thickness acellular dermal matrix grafts.Conclusion: EuroGTPII methodologies allow us to identify the risks and ensure the correct definition of pre-clinical assessments required to address and mitigate the potential risk consequences, before proceeding with clinical use of the new allografts in patients.Graphical Abstract: Keywords: EuroGTPII methodology, acellular dermis, risk assessment, quality, safety |
Audience | Academic |
Author | Pérez, Maria Luisa Castells-Sala, Cristina Fariñas, Oscar Vilarrodona, Anna López-Chicón, Patricia Tabera, Jaime Piteira, Ana Rita |
Author_xml | – sequence: 1 givenname: Patricia surname: López-Chicón fullname: López-Chicón, Patricia organization: Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain – sequence: 2 givenname: Maria Luisa surname: Pérez fullname: Pérez, Maria Luisa organization: Vall Hebron Institute of Research (VHIR), Barcelona, Spain – sequence: 3 givenname: Cristina surname: Castells-Sala fullname: Castells-Sala, Cristina organization: Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain – sequence: 4 givenname: Ana Rita surname: Piteira fullname: Piteira, Ana Rita organization: Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain – sequence: 5 givenname: Oscar surname: Fariñas fullname: Fariñas, Oscar organization: Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain – sequence: 6 givenname: Jaime surname: Tabera fullname: Tabera, Jaime organization: Biomedical Research Institute (IIB-Sant Pau; SGR1113), Barcelona, Spain – sequence: 7 givenname: Anna surname: Vilarrodona fullname: Vilarrodona, Anna organization: Vall Hebron Institute of Research (VHIR), Barcelona, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37425344$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk1vEzEQhleoiLaBG2dkCQlxYIO_1t5wQSGkJVIjPhokbtbE601cvOtg71bkwm_HaULVSMiHGY2feeUZv-fZSetbk2XPCR5SwuXbxeTbfHjNCS4kf5SdESLLnGL24-QuF7lgTJxm5zHeYMzFaESeZKdMclowzs-yP197cLbbouUWfTTRrtp3Kd4a5zeNaTvka3QNtUHQVmha11aDtr6P6KJ3Ll-srf7ZmhjRWBvnegchNYcGHJpDF-xv9AGiqZBv0bQP_nLxZTZDc9OtfeWdX1kTn2aPa3DRPDvEQfb9YrqYfMqvPl_OJuOrXBdYdDlf4oJqjI0RoiQjUQpe14xhSRmtKlmDGHFtuCZYaEizlbucaQIVlNVSEDbIZnvdysON2gTbQNgqD1bdFXxYKQid1c4oLfGyJIQzDILzEYYCjJaUYl3oUhKWtN7vtTb9sjGVTmsK4I5Ej29au1Yrf6sIZrSQ6W8G2euDQvC_ehM71di42yC0Ji1X0ZKNKE9jyoS-3KMrSG-zbe2TpN7haiwFZpwSzBM1_A-VTmUaq5NfapvqRw2vHjSsDbhuHb3rO-vbeAy-2YM6-BiDqe_nJFjt_Kd2_lMH_yX8xcPd3MP_DMf-AjBT1W8 |
Cites_doi | 10.1007/s10561-008-9073-4 10.1177/1091581819883820 10.1007/s12178-020-09658-4 10.1016/j.burns.2009.03.007 10.1007/s10561-012-9333-1 10.1016/j.biomaterials.2011.01.057.An 10.1016/j.jamcollsurg.2016.11.017 10.1016/j.arthro.2009.05.012 10.1093/humrep/deaa146 10.2147/bsam.s115187 10.1097/sla.0000000000004454 10.1016/j.jse.2019.05.043 10.1016/j.eats.2015.07.006 10.1016/j.amjsurg.2006.08.029 10.1007/s10561-020-09813-8 10.1016/j.eats.2018.02.010 10.1007/s12178-018-9466-3 10.1097/SAP.0000000000001692 10.1093/intqhc/mzz048 10.1016/j.tice.2021.101572 10.1097/PRS.0000000000004109 10.1016/j.cryobiol.2021.01.013 10.1097/01.sap.0000254410.91132.a8 10.1007/s10561-017-9625-6 10.1016/j.arthro.2011.06.038 10.1016/j.burns.2007.02.009 10.1001/archsurg.2009.12 |
ContentType | Journal Article |
Copyright | 2023 López-Chicón et al. COPYRIGHT 2023 Dove Medical Press Limited 2023 López-Chicón et al. 2023 López-Chicón et al. |
Copyright_xml | – notice: 2023 López-Chicón et al. – notice: COPYRIGHT 2023 Dove Medical Press Limited – notice: 2023 López-Chicón et al. 2023 López-Chicón et al. |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.2147/TCRM.S410574 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | López-Chicón et al |
EISSN | 1178-203X |
EndPage | 578 |
ExternalDocumentID | oai_doaj_org_article_c70b811430a64490a5aec7220c5c8713 A760342104 10_2147_TCRM_S410574 37425344 |
Genre | Journal Article |
GeographicLocations | Spain |
GeographicLocations_xml | – name: Spain |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 0YH 123 29Q 2WC 53G 5VS 6PF 7RV 7X7 8AO 8FI 8FJ 8G5 AAWTL ABDBF ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AQUVI AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI CCPQU CS3 DIK DWQXO E3Z EBD EBS EJD ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IHW ITC KQ8 M0T M2O M48 M~E NAPCQ NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RNS RPM TR2 TUS UKHRP VDV AAYXX CITATION TDBHL 7X8 5PM |
ID | FETCH-LOGICAL-c506t-4b052c00ee668196864ff3307232dd7fa694ce4c106ca7428e4c13c1ada8db613 |
IEDL.DBID | RPM |
ISSN | 1176-6336 1178-203X |
IngestDate | Thu Sep 05 15:48:14 EDT 2024 Tue Sep 17 21:30:22 EDT 2024 Sat Oct 05 06:08:26 EDT 2024 Thu Feb 22 23:50:19 EST 2024 Fri Feb 02 04:43:07 EST 2024 Tue Aug 20 22:08:30 EDT 2024 Thu Sep 26 15:47:00 EDT 2024 Sat Sep 28 08:09:35 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | EuroGTPII methodology risk assessment acellular dermis safety quality |
Language | English |
License | 2023 López-Chicón et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c506t-4b052c00ee668196864ff3307232dd7fa694ce4c106ca7428e4c13c1ada8db613 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325720/ |
PMID | 37425344 |
PQID | 2839249687 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c70b811430a64490a5aec7220c5c8713 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10325720 proquest_miscellaneous_2839249687 gale_infotracmisc_A760342104 gale_infotracacademiconefile_A760342104 gale_healthsolutions_A760342104 crossref_primary_10_2147_TCRM_S410574 pubmed_primary_37425344 |
PublicationCentury | 2000 |
PublicationDate | 2023-01-01 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | Therapeutics and clinical risk management |
PublicationTitleAlternate | Ther Clin Risk Manag |
PublicationYear | 2023 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | Chalmers (ref19) 2020; 13 Becker (ref32) 2019; 38 Gelber (ref12) 2018; 7 Trias (ref6) 2019; 21 Saegeman (ref30) 2008; 34 Sobti (ref10) 2018; 141 Barber (ref21) 2009; 25 ref2 ref1 Wall (ref22) 2018; 11 Lierman (ref8) 2021; 100 Espinosa-De-Los-Monteros (ref27) 2007; 58 Khoo (ref31) 2010; 36 Ghetti (ref15) 2017; 5 Pérez (ref18) 2021; 72 Maxwell (ref25) 2019; 82 Avanzi (ref20) 2019; 28 Diaz (ref24) 2009; 144 Albo (ref28) 2006; 192 Hirahara (ref23) 2015; 4 Trias (ref4) 2019; 32 Trias (ref7) 2020; 35 Richters (ref14) 2008; 9 Asaad (ref13) 2020 Barber (ref11) 2012; 28 Dragúňová (ref17) 2017; 18 Garvey (ref26) 2017; 224 ref3 Hogg (ref16) 2013; 14 Crapo (ref29) 2011; 32 ref5 Tognetti (ref9) 2017; 5 |
References_xml | – ident: ref1 – volume: 9 start-page: 309 year: 2008 ident: ref14 publication-title: Cell Tissue Bank doi: 10.1007/s10561-008-9073-4 contributor: fullname: Richters – ident: ref3 – ident: ref5 – volume: 38 start-page: 6S year: 2019 ident: ref32 publication-title: Int J Toxicol doi: 10.1177/1091581819883820 contributor: fullname: Becker – volume: 13 start-page: 561 year: 2020 ident: ref19 publication-title: Curr Rev Musculoskelet Med doi: 10.1007/s12178-020-09658-4 contributor: fullname: Chalmers – volume: 36 start-page: 897 year: 2010 ident: ref31 publication-title: Burns doi: 10.1016/j.burns.2009.03.007 contributor: fullname: Khoo – volume: 14 start-page: 465 year: 2013 ident: ref16 publication-title: Cell Tissue Bank doi: 10.1007/s10561-012-9333-1 contributor: fullname: Hogg – volume: 32 start-page: 3233 year: 2011 ident: ref29 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2011.01.057.An contributor: fullname: Crapo – volume: 224 start-page: 341 year: 2017 ident: ref26 publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2016.11.017 contributor: fullname: Garvey – volume: 25 start-page: 1233 year: 2009 ident: ref21 publication-title: J Arthrosc Relat Surg doi: 10.1016/j.arthro.2009.05.012 contributor: fullname: Barber – volume: 35 start-page: 1821 year: 2020 ident: ref7 publication-title: Hum Reprod doi: 10.1093/humrep/deaa146 contributor: fullname: Trias – volume: 5 start-page: 41 year: 2017 ident: ref9 publication-title: J Biorepository Sci Appl Med doi: 10.2147/bsam.s115187 contributor: fullname: Tognetti – year: 2020 ident: ref13 publication-title: Ann Surg doi: 10.1097/sla.0000000000004454 contributor: fullname: Asaad – volume: 28 start-page: 1918 year: 2019 ident: ref20 publication-title: J Shoulder Elb Surg doi: 10.1016/j.jse.2019.05.043 contributor: fullname: Avanzi – volume: 4 start-page: e637 year: 2015 ident: ref23 publication-title: Arthrosc Tech doi: 10.1016/j.eats.2015.07.006 contributor: fullname: Hirahara – volume: 192 start-page: 12 year: 2006 ident: ref28 publication-title: Am J Surg doi: 10.1016/j.amjsurg.2006.08.029 contributor: fullname: Albo – volume: 21 start-page: 189 year: 2019 ident: ref6 publication-title: Cell Tissue Bank doi: 10.1007/s10561-020-09813-8 contributor: fullname: Trias – volume: 5 start-page: 443 year: 2017 ident: ref15 publication-title: Ann Ital Chir contributor: fullname: Ghetti – volume: 7 start-page: e661 year: 2018 ident: ref12 publication-title: Arthrosc Tech doi: 10.1016/j.eats.2018.02.010 contributor: fullname: Gelber – volume: 11 start-page: 122 year: 2018 ident: ref22 publication-title: Curr Rev Musculoskelet Med doi: 10.1007/s12178-018-9466-3 contributor: fullname: Wall – volume: 82 start-page: 435 year: 2019 ident: ref25 publication-title: Ann Plast Surg doi: 10.1097/SAP.0000000000001692 contributor: fullname: Maxwell – ident: ref2 – volume: 32 start-page: 80 year: 2019 ident: ref4 publication-title: Int J Qual Heal Care doi: 10.1093/intqhc/mzz048 contributor: fullname: Trias – volume: 72 start-page: 101572 year: 2021 ident: ref18 publication-title: Tissue Cell doi: 10.1016/j.tice.2021.101572 contributor: fullname: Pérez – volume: 141 start-page: 541 year: 2018 ident: ref10 publication-title: Plast Reconstr Surg doi: 10.1097/PRS.0000000000004109 contributor: fullname: Sobti – volume: 100 start-page: 164 year: 2021 ident: ref8 publication-title: Cryobiology doi: 10.1016/j.cryobiol.2021.01.013 contributor: fullname: Lierman – volume: 58 start-page: 264 year: 2007 ident: ref27 publication-title: Ann Plast Surg doi: 10.1097/01.sap.0000254410.91132.a8 contributor: fullname: Espinosa-De-Los-Monteros – volume: 18 start-page: 153 year: 2017 ident: ref17 publication-title: Cell Tissue Bank doi: 10.1007/s10561-017-9625-6 contributor: fullname: Dragúňová – volume: 28 start-page: 8 year: 2012 ident: ref11 publication-title: Arthrosc J Arthrosc Relat Surg doi: 10.1016/j.arthro.2011.06.038 contributor: fullname: Barber – volume: 34 start-page: 205 year: 2008 ident: ref30 publication-title: Burns doi: 10.1016/j.burns.2007.02.009 contributor: fullname: Saegeman – volume: 144 start-page: 209 year: 2009 ident: ref24 publication-title: Arch Surg doi: 10.1001/archsurg.2009.12 contributor: fullname: Diaz |
SSID | ssj0046991 |
Score | 2.3415954 |
Snippet | The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular dermal... Background: The activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular... BackgroundThe activities of tissue establishments are constantly and rapidly evolving. The development of a new type of allograft, full-thickness acellular... Patricia López-Chicón,1,2,* Maria Luisa Pérez,1,3,* Cristina Castells-Sala,1,2,* Rita A Piteria,1,2,* Oscar Fariñas,1,2 Jaime Tabera,1,2 Anna Vilarrodona1,3... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 567 |
SubjectTerms | acellular dermis Analysis eurogtpii methodology Mechanical properties Medical research Medicine, Experimental Methodology Methods quality Risk assessment safety |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQnnhB_CYw4JBgvCzMcezE5a0bGxtSUcUyqW-W49jaBEoRKxJ94W_nzm67RjzwwlsVO1F9d777zjp_x9jr1tXcS2tzxA5dLoPyudV0bhXQgHjwqqzoNvLkc3V6IT_N1Gyr1RfVhCV64CS4A_xWqxG0l9xi6B5xq6x3tRDcKYdgP_F8FmqdTCUfjDlf7JVXFDXZQTlLJe_Uk-egOfoyeXdO1Y21HASjyNn_t2feCk3DssmtOHRyl91ZAUgYpz9-j93y_X22N00M1Mt9aG4uVF3vwx5Mb7iplw_Y78SZsYR2CR9i8cZ72KobgnmAcxs82L6DY2KXsI6KZIEy1by5vHJfyTXCmM77qYAVX8avf4MJMf3_gkOMiR3Me6BD_o_N9OwMJrFFdXSx_vohuzg5bo5O81ULhtwpXi1y2XIlHOfeVxVih0pXMoQS_QICsa6rg61G0nnpMLF0FrNsTb9LV9jO6q5FqPCI7fTz3j9hIFrZuaAKKxzmpHqkZadH3FmEjCIgqsjYm7UuzPfEtGEwQyGdGdKZWeksY4ekqM0c4seOD9BqzMpqzL-sJmMvSc0mXTbd7HIzriviRMQcNWNv4wza56htFHe6roCLIcaswczdwUzcn24w_GptSoaGqKit96g6IwicShRqnbHHybQ2qypRmKqU-LYeGN1g2cOR_uoy0oMTRaKqBX_6PwT1jN0WCOvSodMu21n8-OmfIwxbtC_ijvsDTZMs9g priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELbGeOEF8ZuwAUaC8bJsjmMnLhJC3djYkIIqlkp9sxzHZhNTOtoiLS_87dwladdoSLxVtV3Jvjv7-9zzd4S8LWzKnDAmBOxQhsJLFxqF91YeHIh5J-MEXyNn35KTsfg6kZMNsqw22i3g_J_UDutJjWeXe9e_6k8Q8B8xjTkS6X5--D3bO8N8xVTcIXe5iAX6eiZW_ycAB2xq50VRin4RT9oU-Fuje4dTo-F_e6deO6r6aZRr59LxA3K_A5R02HrAQ7LhqkdkZ9QqUte7NL95YDXfpTt0dKNVXT8mf1oNjZoWNf3cJHN8oGt5RHTq6ZnxjpqqpEeoNmEsJs1SZK5hfn5hf-JWSYd4_48JrTAYfv2SZqj8f00P4Iws6bSieOn_JR-dntKsKVndbLlu_oSMj4_yw5OwK8kQWsmSRSgKJrllzLkkASyRqER4H8M-AcCsLFNvkoGwTlggmtYA61b4ObaRKY0qC4AOT8lmNa3cc0J5IUrrZWS4BY6qBkqUasCsAQjJPaCMgLxb2kJftcobGhgL2kyjzXRns4AcoKFWfVAvu_liOvuhu_DT4JGFAuoXMwMAcMCMNM6mnDMrLVDGOCCv0cy6fXy6ino9TBPUSATOGpD3TQ_0RLA2LHf7fAEmgwpavZ7bvZ4Qr7bX_GbpShqbMMmtcmA6zRGsCljUNCDPWtdazSqGxZSxgNGq53S9afdbqovzRi4cJRNlytmL_85xi9zjgOHaG6ZtsrmY_XYvAXMtildNOP0FAvUpCQ priority: 102 providerName: Scholars Portal |
Title | Quality by Design: Development of Safe and Efficacious Full-Thickness Acellular Dermal Matrix Based on EuroGTPII Methodologies |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37425344 https://search.proquest.com/docview/2839249687 https://pubmed.ncbi.nlm.nih.gov/PMC10325720 https://doaj.org/article/c70b811430a64490a5aec7220c5c8713 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLa2ceGC-E1gFCPBuCytGzu2y60tHRtSpmjrpN4ix3G2ii2dtiLRC3877zlN14gblyqq7aj2e8_-nvv5MyGfcquYE8aEgB2KUJSxC43GfasSHIiVLuYSTyMnp_L4QvyYxbMdIpuzMJ60b_N5t7q-6VbzK8-tvL2xvYYn1kuTMYrAxSpivV2yqzhvcvR6_oV8z9-T1-8rGUqOf04i3R3v4-lNx2dJ9xyZjUq0FiKv1__vrLy1LLUpk1tr0NFT8mQNHumw_pHPyI6rnpODtFafXh3S6cNhqvtDekDTB13q1Qvyp9bLWNF8Rb954sZXusUZoouSnpvSUVMVdILKEsYiQZZilhpOr-b2J06LdIh7_Uhehcbw9muaoMr_bzqC9bCgi4riBv_3aXpyQhN_PbWfXt39S3JxNJmOj8P19QuhjZlchiJncWQZc05KwA1SS1GWHOYEAGFFoUojB8I6YSGptAYybI3P3PZNYXSRA0x4RfaqReXeEBrlorBl3DeRhXxUD7Qo9IBZA3AxKgFRBORzY4vstlbZyCA7QZtlaLNsbbOAjNBQmzqoje2_WNxdZmsPycD7cg1pHmcGwN6Amdg4q6KI2dhCesgD8gHNnNUHTTcRng2VRD1EyE8D8sXXwBgHa8Nw10cVoDOoltWqud-qCbFpW8UfG1fKsAgJbZUD02URAlMBg6oC8rp2rU2vOAxmzAW01i2na3W7XQKR4qXBm8h4-_9N35HHEQC5eptpn-wt73659wC8lnkHom2mOuTRaHKannX89gV8JkJ3fAT-BbyQMWo |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27955,27956,31753,33778,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwGLXGOMCF3z8CgxkJxmVJ3cR2Um5d2WhhmSqWid0sx3FYtS2dtk6iHPjb-T6n6Ro4wa2q7aq2Xz6_L35-JuRtbmJmudY-cIfC56Wwvk7wvVUJAGKlFZHE08jpgRwe8c_H4niNyOYsjBPtm3wSVGfnQTU5cdrKi3PTaXRinXE6QBM4EYesc4vchgc2FE2WXkdgyPjcTXndbix9GeH2JAre8UaeTjb4mgaHqG2MeWspco79f8fllYWpLZpcWYX27pNvzf-vxSenwfUsD8zPP6wd_72DD8i9BTGl_br8IVmz1SOyNa6drefbNLs5qHW1Tbfo-Mbzev6Y_Kq9OOY0n9OPThTyga7okei0pIe6tFRXBd1F1wptUHxLMQP2s5OJOcWQS_u4j4DCWGgMv35GU7xB4AfdgbW2oNOK4ubBp2w8GtHUXX3tQre9ekKO9nazwdBfXO3gG8HkzOc5E6FhzFopgZPIRPKyjCDeAMErirjUsseN5QYSVqMhe0_wc2S6utBJkQMFeUrWq2llnxMa5rwwpejq0ECum_QSXiQ9ZjRQ0bAEtuKRd80sq4vawUNB5oNoUIgGtUCDR3YQAss66LvtvphefleLyVGA7DyBFDJiGohkj2mhrYnDkBlhIPWMPLKJAFL1IdZl9FD9WKLXIuS-HnnvamD8ABzBcNfHIKAz6MTVqrnRqgnPvWkVv2lAqrAIxXKVhalTIZJeDoMae-RZDdplryIYTBFxaJ204NzqdrsEQOpsxxtQvvj_ppvkzjBL99X-6ODLS3I3BMJYv87aIOuzy2v7CgjeLH_tnubf4_dPNQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgSIgXvj8KgxkJxsuSuonjpLx13coKZIpYJk3ag-U4Nqu2pdXaSZQHfjv35qNr4G1vVWJXsn18fW58fEzIh0yHzHClHOAOucNtYBwV4XcrCwBi1gS-wNPI8aE4OOZfT4KTWlU5r2WVhc4mbnFx6RaTs1JbObvU3UYn1k3iIZrABaHHurPcdu-SezBpvbDJ1KsoDFlfeVterxcKR_i4RYmid7yVp5sOf8TuEeobQ95ajkrX_v9j89ri1BZOrq1Eo0fktGlDJUA5d68Xmat__2PveLtGPiYPa4JKB1WZJ-SOKZ6S7aRyuF7u0PTmwNZ8h27T5Mb7evmM_Kk8OZY0W9K9Uhzyma7pkujU0iNlDVVFTvfRvUJpFOFSzISd9GyizzH00gHuJ6BAFirDv1_QGG8S-EV3Yc3N6bSguInwJU3GYxqXV2CXIdzMn5Pj0X46PHDqKx4cHTCxcHjGAk8zZowQwE1EJLi1PsQdIHp5Hlol-lwbriFx1Qqy-Ah_-7qnchXlGVCRF2SjmBbmFaFexnNtg57yNOS8UT_iedRnWgEl9Sywlg752Iy0nFVOHhIyIESERETIGhEdsoswWJVB_-3ywfTqp6wHSALCswhSSZ8pIJR9pgJldOh5TAcaUlC_Q7YQRLI6zLqKInIQCvRchBy4Qz6VJTCOAJagu6vjENAYdORqldxslYT5r1uv3zdAlfgKRXOFgaGTHpJfDp0adsjLCrirVvnQmYHPoXbUgnSr2e03ANTSfrwB5uvbV90i95O9kfw-Pvz2hjzwgDdWX7U2ycbi6tq8BZ63yN6VE_ovUhpRtQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quality+by+Design%3A+Development+of+Safe+and+Efficacious+Full-Thickness+Acellular+Dermal+Matrix+Based+on+EuroGTPII+Methodologies&rft.jtitle=Therapeutics+and+clinical+risk+management&rft.au=Piteira%2C+Ana+Rita&rft.au=Lopez-Chicon%2C+Patricia&rft.au=Perez%2C+Maria+Luisa&rft.au=Castells-Sala%2C+Cristina&rft.date=2023-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-203X&rft.volume=19&rft.spage=567&rft_id=info:doi/10.2147%2FTCRM.S410574&rft.externalDBID=n%2Fa&rft.externalDocID=A760342104 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1176-6336&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1176-6336&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1176-6336&client=summon |